{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/otitis-externa/prescribing-information/oral-clarithromycin/","result":{"pageContext":{"chapter":{"id":"b186879f-d6d6-5afa-84d8-845ba42605c1","slug":"oral-clarithromycin","fullItemName":"Oral clarithromycin","depth":2,"htmlHeader":"<!-- begin field c5d11acc-73d4-4ec1-aa1f-3a5fd7721c41 --><h2>Oral clarithromycin</h2><!-- end field c5d11acc-73d4-4ec1-aa1f-3a5fd7721c41 -->","summary":"","htmlStringContent":"<!-- begin item 0d7e3b7f-99cd-4116-b3bb-d1eb60b5be5f --><!-- end item 0d7e3b7f-99cd-4116-b3bb-d1eb60b5be5f -->","topic":{"id":"f876df90-ac8c-5343-ac27-cf0dce71d872","topicId":"0999db7d-67e0-4462-a7d7-c1cd5f57cf6a","topicName":"Otitis externa","slug":"otitis-externa","lastRevised":"Last revised in February 2018","chapters":[{"id":"66707be8-e82b-56aa-a7d4-2e83fd4e34f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc9f278a-f789-50fb-a43c-1b9fde28ef7f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"042a16b9-3050-5ecb-9199-e9f18527c183","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"736969ef-5779-5f8d-b3c8-95bc2137ea11","slug":"changes","fullItemName":"Changes"},{"id":"d74a591d-a4fa-5fa7-9a79-11341d8ad57c","slug":"update","fullItemName":"Update"}]},{"id":"922f046d-5114-504a-b7dd-1754b6b9de95","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"07126be4-c022-5eca-b29c-7b3bf9638295","slug":"goals","fullItemName":"Goals"},{"id":"fa385cc8-0093-54cd-ab27-8bf1de604bd7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5717d539-e1a2-5f48-9c65-a6e1c3523910","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d8e4c4a2-74ce-589f-856b-dfd3f0c0e8d9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b72bcdb9-0860-5e4e-ac10-b0ddef3274ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dc6ecfda-2678-5466-b11f-c04e4a210a6c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c4e7ed77-cefa-531a-a475-7af487f17915","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6eaf075-9623-547f-88d8-987fc90c5bdf","slug":"definition","fullItemName":"Definition"},{"id":"c8342f48-2446-51c8-b164-710650b2b937","slug":"causes","fullItemName":"Causes"},{"id":"dfaffdb8-3a14-5de7-ae1f-aab5dd341ee9","slug":"complications","fullItemName":"Complications"},{"id":"a5cb2def-cfd9-5728-95fa-4e9bbceb7fd8","slug":"prognosis","fullItemName":"Prognosis"},{"id":"63c036e7-6c79-5164-bded-0583fa30260b","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"8aa1bc32-b762-5d5a-bfe3-378af9c545f3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c7df346e-5420-50ae-98ff-4e00234699d9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f3f8f6dd-87d1-5688-8f98-84eb3ec59ca5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1851ae55-865c-5488-902c-54822a2a76dd","fullItemName":"Management","slug":"management","subChapters":[{"id":"9f7ce67c-9805-5fef-a1f9-cc88a9085674","slug":"localized-otitis-externa","fullItemName":"Scenario: Localized otitis externa"},{"id":"d753f65b-ae51-5d11-8b85-4d833a89a428","slug":"acute-diffuse-otitis-externa","fullItemName":"Scenario: Acute diffuse otitis externa"},{"id":"7f39d3cc-526b-51bc-b091-6399e805f3cb","slug":"chronic-diffuse-otitis-externa","fullItemName":"Scenario: Chronic diffuse otitis externa"}]},{"id":"aa30911a-20a0-5191-ba4e-f48610d404b2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43fc276-0f45-52d9-97a9-394af935add3","slug":"topical-ear-preparations","fullItemName":"Topical ear preparations"},{"id":"b49a03f2-59c1-56ed-b894-9e01ce84d1a8","slug":"oral-analgesics","fullItemName":"Oral analgesics"},{"id":"fd97664d-7f15-5f36-a10c-7bcad2d057f2","slug":"oral-flucloxacillin","fullItemName":"Oral flucloxacillin"},{"id":"b186879f-d6d6-5afa-84d8-845ba42605c1","slug":"oral-clarithromycin","fullItemName":"Oral clarithromycin"}]},{"id":"8c363337-fc91-521b-a609-58b9b0ba4d8b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9feebcb7-db7f-5a9f-a9a7-89f401ebca13","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8fc4ebd8-033e-5184-bb1e-cc1bd7de86e2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7580e3ff-a6f6-5f7b-9254-6772074d8d7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5162da22-b23f-5934-87a8-4aa96029fcde","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"babd7947-def4-5d00-a46e-c68902688a88","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"18fd5166-b294-56f8-8cf1-c2e4e2bfa31d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ae1ef912-929f-5085-9b08-d75ce3e016b7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"aa30911a-20a0-5191-ba4e-f48610d404b2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"292e0750-5925-5c54-a912-a60b005e96eb","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 794e8788-bc8b-4b94-a241-634eb39b15c8 --><h3>What dose of clarithromycin should I prescribe?</h3><!-- end field 794e8788-bc8b-4b94-a241-634eb39b15c8 -->","summary":"","htmlStringContent":"<!-- begin item c1f1f163-7e43-4d5a-b45e-b9d2516f0d06 --><!-- begin field 1fcd6603-7078-4a11-a264-c8a0bc9565f4 --><ul><li>Clarithromycin doses:<ul><li>Adults and children older than 12 years of age — 250 mg (increasing to 500 mg in severe infection), twice daily for 7 days.</li><li>Children 1 month to 11 years of age:<ul><li>Body weight less than 8 kg — 7.5 mg per kg twice daily.</li><li>Body weight 8–11 kg — 62.5 mg twice daily.</li><li>Body weight 12–19 kg — 125 mg twice daily.</li><li>Body weight 20–29 kg — 187.5 mg twice daily.</li><li>Body weight 30–40 kg — 250 mg twice daily.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">BNF for Children, 2017</a>]</p><!-- end field 1fcd6603-7078-4a11-a264-c8a0bc9565f4 --><!-- end item c1f1f163-7e43-4d5a-b45e-b9d2516f0d06 -->","subChapters":[]},{"id":"cb2e422e-c377-535b-b983-d68eebcc1602","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2bce9dbf-63b5-45bb-a0e5-84581007d6b8 --><h3>What are the adverse effects of clarithromycin?</h3><!-- end field 2bce9dbf-63b5-45bb-a0e5-84581007d6b8 -->","summary":"","htmlStringContent":"<!-- begin item 0990fdc6-4813-4344-974b-a8e7b07f8c20 --><!-- begin field 91c12058-92b9-4728-b718-8fbfe6d0fb9c --><ul><li>Clarithromycin is generally well tolerated. </li><li>The most common adverse effects are gastrointestinal — such as nausea, vomiting, dyspepsia, and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin.</li><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Less common adverse effects include rash and hepatotoxicity.</li><li>Very rarely, QT prolongation, ventricular tachycardia, and Torsade de Pointes arrhythmia have been reported.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">ABPI, 2016b</a>]</p><!-- end field 91c12058-92b9-4728-b718-8fbfe6d0fb9c --><!-- end item 0990fdc6-4813-4344-974b-a8e7b07f8c20 -->","subChapters":[]},{"id":"e9af12cb-21d9-5793-82a9-911123fb34e0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 041c786c-82bf-459d-8880-d04ba9ef8365 --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field 041c786c-82bf-459d-8880-d04ba9ef8365 -->","summary":"","htmlStringContent":"<!-- begin item 63e6b57c-7950-424f-b335-f73f1f7925fb --><!-- begin field 91e94900-a2ec-4ee4-aa44-ca3988077dc2 --><ul><li><strong>Do not prescribe clarithromycin</strong> to people with:<ul><li>Known hypersensitivity to clarithromycin or other macrolide antibiotics.</li><li>A history of QT prolongation or ventricular arrhythmia, including Torsade de Pointes.</li><li>Hypokalaemia.</li><li>Severe hepatic failure.</li></ul></li><li>Clarithromycin is also contraindicated for people taking certain drugs.</li><li><strong>Prescribe clarithromycin with caution</strong> in people with:<ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with clarithromycin.</li><li>Moderate to severe renal impairment — use half the dose if the estimated Glomerular Filtration Rate (eGFR) is less than 30mL/min/1.73 m<sup>2</sup>. Avoid Klaricid XL® (clarithromycin 500 mg prolonged release once daily tablets) or other modified release clarithromycin preparations in people with an eGFR less than 30 mL/min/1.73 m<sup>2</sup>. </li><li>Conditions that predispose to QT interval prolongation, such as electrolyte disturbances and people taking drugs that prolong the QT interval — macrolides can also prolong the QT interval, increasing the risk of Torsades de Pointes arrhythmia. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">BNF 72, 2016</a>]</p><!-- end field 91e94900-a2ec-4ee4-aa44-ca3988077dc2 --><!-- end item 63e6b57c-7950-424f-b335-f73f1f7925fb -->","subChapters":[]},{"id":"835d3851-0960-52ae-87e2-32c02750a2c0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4250eafd-c4cc-4eb5-a0c8-07aab106851f --><h3>What are the important drug interactions with clarithromycin?</h3><!-- end field 4250eafd-c4cc-4eb5-a0c8-07aab106851f -->","summary":"","htmlStringContent":"<!-- begin item b64a477a-99f0-4753-bd64-2f9229e0bc1b --><!-- begin field e8a74e1f-47d9-402e-9557-9e449a1dc242 --><ul><li><strong>Drug interactions with clarithromycin include:</strong><ul><li><strong>Pimozide </strong>— do not prescribe with clarithromycin as concurrent use may result in QT prolongation, cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes.</li><li><strong>Ergotamine and dihydroergotamine</strong> — do not prescribe with clarithromycin as concurrent use may result in acute ergot toxicity. </li><li><strong>Colchicine</strong> — avoid concomitant administration.</li><li><strong>Carbamazepine</strong> — monitor carbamazepine levels within 3–5 days of starting clarithromycin, and adjust dose accordingly. Clarithromycin can increase carbamazepine levels, causing carbamazepine toxicity (may present as nausea and vomiting, ataxia, and drowsiness).</li><li><strong>Other drugs that prolong the QT interval</strong> — if possible, avoid giving clarithromycin to a person who is already taking a drug that can potentially prolong the QT interval.</li><li><strong>Statins</strong> — there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin. Consider temporarily stopping simvastatin during short-term treatment with clarithromycin. </li><li>For atorvastatin — avoid concurrent use with clarithromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe clarithromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with clarithromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.<strong> </strong></li></ul></li><li><strong>Warfarin</strong> — increase monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. Clarithromycin may enhance the effect of warfarin. </li><li><strong>Oral hypoglycaemic drugs and insulin</strong> — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly and adjust the antidiabetic drug (and/or insulin) dose accordingly. </li></ul></li><li><strong>Calcium channel blockers (CCBs)</strong> — due to an increased risk of hypotension, caution is advised with the concurrent use of clarithromycin and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">FSRH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-externa/references/\">BNF 72, 2016</a>]</p><!-- end field e8a74e1f-47d9-402e-9557-9e449a1dc242 --><!-- end item b64a477a-99f0-4753-bd64-2f9229e0bc1b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}